676266-31-2 Usage
Uses
Used in Pharmaceutical Industry:
4-Pyridinecarboxamide, N-[2-Methyl-5-phenyl-3-[[4-[3-(trifluoroMethyl)phenyl]-1-piperazinyl]Methyl]-1H-pyrrol-1-yl]is used as a potential pharmaceutical agent for its complex molecular structure that may exhibit bioactivity. The presence of various functional groups, such as the pyridinecarboxamide and trifluoromethyl phenyl, indicates that 4-PyridinecarboxaMide, N-[2-Methyl-5-phenyl-3-[[4-[3-(trifluoroMethyl)phenyl]-1-piperazinyl]Methyl]-1H-pyrrol-1-yl]- could interact with biological targets, making it a candidate for drug development. However, the specific therapeutic applications and mechanisms of action need to be determined through additional research and clinical trials.
Check Digit Verification of cas no
The CAS Registry Mumber 676266-31-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,7,6,2,6 and 6 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 676266-31:
(8*6)+(7*7)+(6*6)+(5*2)+(4*6)+(3*6)+(2*3)+(1*1)=192
192 % 10 = 2
So 676266-31-2 is a valid CAS Registry Number.
676266-31-2Relevant academic research and scientific papers
PREPARATION OF [2-METHYL-5-PHENYL-3-(PIPERAZIN-1-YLMETHYL)] PYRROLE DERIVATIVES
-
Page/Page column 16-18, (2008/06/13)
A process for the preparation of compounds of Formula (I) and their pharmaceutically acceptable acid addition salt wherein R1 is phenyl or substituted phenyl, R3 is selected from a group of formula (a), n = 0-2 and X = -NCH3/su
Antimycobacterial pharmaceutical composition
-
Page/Page column 11, (2008/06/13)
An antimycobacterial combination and composition for treating tuberculosis are described. The compounds used are N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide of formula (I) or a pharmaceutically ac
PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS
-
Page 25-26, (2010/02/06)
Novel pyrrole derivatives of formula (I), and their pharmaceutically acceptable acid addition salts having superior antimycobacterial activity against clinically sensitive as well as resistant strains of Mycobacterium tuberculosis as well as having lesser
